Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Revaccination With Intradermal vs Aerosol BCG in Healthy Adults With and Without Type 2 Diabetes
NCT06246851Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Apr 2024
- Primary completion
- Aug 2028
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of bacillus calmette-guerin substrain danish 1331 live antigen in Tuberculosis (TB) (3 arms), sponsored by University of Oxford. Primary endpoints: Comparison of immune response between intradermal and aerosol BCG in non-type 2 diabetics at 168 days and Comparison of immune response to intradermal BCG between type 2 diabetics and non-type 2 diabetics at 168 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigen
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06246851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246851.